Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure

BackgroundThis study aimed to investigate the efficacy of immunotherapy, as monotherapy or in combination, comparing to chemotherapy with or without anti-angiogenesis for advanced non-small cell lung cancer (NSCLC) patients progressing to epidermal growth factor receptor (EGFR)-tyrosine kinase inhib...

Full description

Bibliographic Details
Main Authors: Xingyuan Li, Huayan Huang, Yingjia Sun, Qing Jiang, Yongfeng Yu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
immunotherapy
EGFR mutation
progression
EGFR-TKIs
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1265236/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1265236/full

Similar Items